#China #Shenzhen #Clinical Trial #Kexing Biopharm #GB10 Injection

Kexing Biopharm's Innovative GB10 Injection: A New Hope in Ophthalmic Treatment

Kexing Biopharm is making headlines with the introduction of its groundbreaking ophthalmic drug, GB10 Injection, which has recently entered the Phase I clinical trial stage in China. This innovative treatment aims to tackle neovascular age-related macular degeneration (nAMD), a leading cause of blindness for individuals over 50 years old worldwide.

Background of GB10 Injection

Developed independently by Shenzhen Kexing Pharmaceutical Co., Ltd., a 100% subsidiary of Kexing Biopharm, GB10 Injection stands out as a highly concentrated protein-based formulation. The drug incorporates a bispecific antibody targeting both VEGF (Vascular Endothelial Growth Factor) and Ang-2 (Angiopoietin-2), which are crucial in the pathology of various ophthalmic conditions.

The innovative design of GB10 allows for a dosage concentration of 140 mg/ml, which is significantly higher than that of many existing treatments. As a result, this enables a reduced injection volume or an increased dosage, ultimately leading to extended intervals between treatments. Clinical data suggests a possible regimen of an injection every four months, which could significantly improve patients’ therapy adherence and health outcomes.

Importance of the Clinical Trial

The enrollment of the first participant in the Phase I clinical trial signifies a significant milestone for Kexing Biopharm. Preclinical studies exhibited promising results, showcasing the drug's competitive biological activity and efficacy in inhibiting pathological ocular neovascularization, as demonstrated in a laser-induced monkey model of choroidal neovascularization.

The increasing prevalence of nAMD presents a pressing need for effective treatments as digital screen time rises and populations age globally. GB10 Injection, with its proposed extended administration intervals, directly addresses the common challenges faced: frequent injections and low adherence rates among patients.

Kexing Biopharm's Vision and Pipeline

Beyond GB10, Kexing Biopharm is vigorously advancing its research pipeline for ophthalmic antibody treatments, focusing on dual-targeting strategies. The company is also working on launching externally developed ophthalmic products globally, such as biosimilar Aflibercept and Olopatadine Hydrochloride eye drops. These initiatives are expected to bolster Kexing’s presence in international markets and facilitate their goal of continuous innovation and accessibility for high-quality healthcare solutions.

As Kexing Biopharm looks ahead, the commitment to their philosophy of “Precise products, predictable effects, health protection” remains firm. The company aims to not only provide effective ophthalmic treatments but also ensure these options are accessible to patients around the world, fundamentally changing their quality of life.

In conclusion, the initiation of the Phase I clinical trial for GB10 Injection by Kexing Biopharm marks a hopeful leap forward in ophthalmic treatments, particularly for age-related ocular conditions. The innovative formulation and treatment strategy hold a promise that could reshape the landscape of ophthalmic care, benefiting countless patients suffering from nAMD as it continues to progress through its clinical development phases.